HOUSTON and SHANGHAI, Jan. 11, 2021 /PRNewswire/ — NuProbe, a genomics and molecular diagnostics company…
Read More
Rapid Development
Sensitive Mutation and CNV Detection
Low Input DNA
Gene selection and Coverage options
VarMap™: NGS
Features
Affordable
Only 1 million reads for liquid biopsy
Ultrasensitive
Limit of detection down to 0.1% VAF
Quantitative
>95% VAF quantitation accuracy
Sample Flexibility
Compatible with several sample types
Sample Data
VarMap NGS Panels preferentially amplify variant molecules, resulting in a reduction of required sequencing reads by 60-fold compared to deep sequencing approaches.
Products
VarMap™ NSCLC NGS Panel
Detects over 1100 COSMIC mutations in AKT1, ALK, BRAF, DDR2, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, ROS1, and TP53
VarMAP™ Melanoma NGS Panel
Detects over 370 COSMIC mutations in AKT1, AKT3, BRAF, KRAS, MAP2K1, MAP2K2, NRAS, and PIK3CA
CNV+: NGS
Features
Ultrasensitive
Limit of detection down to 0.1% VAF
Quantitative
>95% VAF quantitation accuracy
Quick Turnaround Time
6-hour DNA-to-Library workflow
Sample Flexibility
Compatible with several sample types
Sample Data
CNV+ panels use QASeq technology, which is more sensitive than ddPCR. The panels detect deletions and mutations, that can not be done with IHC. QASeq technology allows analyzing thousands of loci, while ddPCR analyzes 1 locus.
Products
CNV+ Breast Cancer NGS Panel
Detects 84 mutation hotspots in 14 genes and detect ERBB2 Copy Number Variations (CNVs) in a single reaction
VarMap™: Nanopore
Features
Rapid
Ultrafast turnaround enabling 10 hours DNA to results
Ultrasensitive
Limit of detection down to 0.1% VAF
Affordable
Low sequencing cost
Sample Flexibility
Compatible with several sample types
Sample Data
Compared to standard nanopore sequencing, VarMap exhibits roughly 100-fold better mutation VAF limit of detection and roughly 10-fold higher throughput.
Products
VarMap™ AML Nanopore Panel
Detects 254 AML hotspot mutations in 6 genes: FLT3, DNMT3A, IDH1, IDH2, KIT, and NPM1
VarTrace™: qPCR, Sanger
Features
Ultrasensitive
Limit of detection down to 0.1% VAF
Comprehensive
Detects up to 500 COSMIC mutations
Quantitative
Accurate quantitation
Sample Flexibility
Compatible with several sample types
Sample Data
NuProbe’s BDA technology enriches the variant allele frequency (VAF) of mutations by over 200-fold, improving Sanger’s limit of detection of 20% VAF to 0.1% VAF.
Products
VarTrace™ AML Panel
Detects 254 AML hotspot mutations in FLT3, DNMT3A, IDH1, IDH2, KIT, NPM1 genes
VarTrace™ EGFR Assay
Detects 400 mutations in exons 18, 19, 20, and 21 in FFPE and plasma samples
VarTrace™ BRAF Assay
Detects mutations in codons 596–601 in FFPE and plasma samples
Customized qPCR/Sanger Assays and Services
Features
Customizable
Automatically design custom BDA assays
Rapid Turnaround
2-3 days
Ultrasensitive
Limit of detection down to 0.1% VAF
Sample Data
NGSure’s proprietary algorithm designs custom BDA assays with a limit of detection of 0.1% VAF, significantly expanding the range of mutations detected by NGS.
News & Press Releases
HOUSTON, Nov. 16, 2020 /PRNewswire/ — NuProbe, an innovator of genomics…
HOUSTON, June 22, 2020 /PRNewswire/ — NuProbe and Weigao Group…
HOUSTON, June 2, 2020 /PRNewswire/ -- NuProbe, a global precision molecular diagnostics company, announces the world-wide exclusive in-license of two technologies from Rice University. The first, Non-Extensible Oligonucleotides (NEO), will...
Read More
HOUSTON, April 22, 2020 /PRNewswire/ — NuProbe, a molecular diagnostic…
HOUSTON, March 16, 2020 /PRNewswire/ — NuProbe Global, a global…
